Literature DB >> 12581195

Rebound hepatosplenomegaly in type 1 Gaucher disease.

Judit Tóth1, Melinda Erdos, László Maródi.   

Abstract

A 19-year-old male patient with type 1 Gaucher disease was put on regular biweekly infusions of alglucerase. After 1 yr of treatment, hepatic and splenic volumes decreased from 38 and 45 mL/kg to 31 and 34 mL/kg, respectively. In addition, hemoglobin concentration, platelet count and white cell count increased, acid phosphatase level decreased, and the patient gained weight and energy. Despite improvement, the patient refused enzyme replacement therapy (ERT) because of muscle rigidity, chest pain, trembling and anxiety, which he attributed to enzyme substitution. Two and 4.5 year after cessation of therapy, hepatic and splenic volumes increased to 36 and 53 mL/kg and to 53 and 110 mL/kg, respectively. The patient developed non-tractable hematuria because of compression and dislocation of the left kidney by the enlarged spleen, which necessitated splenectomy. This report suggests that cessation of ERT in Gaucher disease may result in severe and complicated rebound visceromegaly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12581195     DOI: 10.1034/j.1600-0609.2003.00010.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.

Authors:  Timothy M Cox; Dominick Amato; Carla Em Hollak; Cecile Luzy; Mariabeth Silkey; Ruben Giorgino; Robert D Steiner
Journal:  Orphanet J Rare Dis       Date:  2012-12-27       Impact factor: 4.123

2.  Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Authors:  Jérôme Stirnemann; Christian Rose; Christine Serratrice; Florence Dalbies; Olivier Lidove; Agathe Masseau; Yves-Marie Pers; Camille Baron; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2015-05-13       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.